Samer Khaled, MD Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses Study Examining The…
Browsing: Acute Lymphoblastic Leukemia
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Outcomes Of The POLLUX And CASTOR Studies. At…
Carol Moreno, MD, PhD Hematologist, University of Barcelona, discusses Recent Advancements In The Treatment Of CLL. At The 60th ASH…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen Discusses Anti-BCMA CAR-T Cell Therapy In MM. At The…
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses ALL As Second Cancer After Treatment, Explorative Study At The…
Pinkal Desai, M.D., Assistant Professor of Medicine Weill Cornell Medical College, Cornell University And Assistant Attending Physician at the New…
Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium,…
Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium,…
Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium,…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rob Pieters, MD, PhD, of Princess…
Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, outlines areas of improvement for treating chronic graft-versus-host…
By understanding the pathogenesis of chronic graft-versus-host disease (GvHD), treatments can be better targeted to improve patient outcomes. In this…
In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, makes predictions on what…
BMIC058
In this video, Robin Foà , MD, from the University of Rome, Rome, Italy, discusses the impact of age on patients…
Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, raises the issue of slow progression of clinical trials in acute…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Oliver Ottmann,…
Here, Robin Foà , MD, from the University of Rome, Rome, Italy, discusses the potential of a chemotherapy-free strategy for patients…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Robin Foà ,…
In this video, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, discusses the importance of allogeneic transplant in different…
Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, points to the need for improving the methodology of measurable residual…
In this video, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, talks about how novel immunotherapeutic options…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel DeAngelo, MD,…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach,…
In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, reflects on the differences between the treatment…
Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, speaks about the advances made in leukemia diagnostics and…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach,…
In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, speaks about the difficulties in diagnosing and…
Dr Jing Pan, of Beijing Boren Hospital, Beijing, P.R. China, discusses a new anti-CD22 CAR T-cell immunotherapy for pediatric relapsed/refractory…
All types of healthcare, including measurable residual disease (MRD) testing should be available to everyone throughout Europe. Speaking from the…
Measurable residual disease (MRD) testing is revolutionizing our ability to determine the disease state of a patient. In this video,…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, Elizabeth Macintyre, MD, PhD, of the…
Julia Snider, PhD, from Precision Health Economics, San Francisco, CA, talks to us about the social value of the CAR…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, in Stockholm, Sweden, Thomas Alexander, MD, PhD, of…
There is an unmet need for treatment options for acute lymphoblastic leukemia (ALL) patients who have relapsed on multiple prior…
Felice Bombaci, from the AIL patient group for chronic myeloid leukemia (CML), Rome, Italy, discusses some important key topics in…
Chemotherapy is becoming increasingly less desirable as a form of treatment, due to its systemic and burdensome nature. Instead, immunotherapy…
Therapies for acute lymphoblastic leukemia (ALL) have constantly been improving. Indeed, 35 years ago the survival rate for children was…
Measurable residual disease (MRD) is an important indicator of disease progression and prognosis. Here, Stephan Grupp, MD, PhD, of the…
While CAR T-cells are a potentially revolutionary therapy option across a variety of cancer types, their associated side effects include…
In this video, Ryan Cassaday, MD, of the University of Washington, Seattle, WA, gives an overview of recent developments in…
Tisagenlecleucel (CTL019), a CAR T-cell agent, was approved for acute lymphoblastic leukemia (ALL) treatment in children and young adults last…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ryan Cassaday, MD, of the…
Neelima Denduluri, MD, discusses the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in…